The paradigm of norgestimate: a third-generation testosterone-derivative progestin with a peripheral anti-androgenic activity and the lowest risk of venous thromboembolism

References

• Del Savio MC, De Fata R, Facchinetti F, et al. Drospirenone 4 mg-only pill (DOP) in 24+4 regimen: a new option for oral contraception. Expert Rev Clin Pharmacol. 2020;13(7): 685–69. DOI:10.1080/17512433.2020.1783247.
   PubMed Web of Science ®Google Scholar
• Schindler AE, Campagnoli C, Druckmann R, et al., Classification and pharmacology of progestins. Maturitas. 2003;46(1): S7–S16.
   PubMedGoogle Scholar
• Grandi G, Mueller MD, Papadia A, et al. Inflammation influences steroid hormone receptors targeted by progestins in endometrial stromal cells from women with endometriosis. J Reprod Immunol. 2016;117:30–38.
   PubMed Web of Science ®Google Scholar
• Kuhl H. Comparative pharmacology of newer progestogens. Drugs. 1996;51(2):188–215.
   PubMed Web of Science ®Google Scholar
• Grandi G, Cagnacci A, Volpe A. Pharmacokinetic evaluation of desogestrel as a female contraceptive. Expert Opin Drug Metab Toxicol. 2014;10(1):1–10.
   PubMed Web of Science ®Google Scholar
• Henzl MR. Norgestimate. J Reprod Med. 2001;46:648–661.
   Web of Science ®Google Scholar
• Back DJ, Madden S, Orme MLE. Gastrointestinal metabolism of contraceptive steroids. AL J Obstetric Gynecol. 1990;163(6):2138–2145.
   PubMed Web of Science ®Google Scholar
• Corson SL. Norgestimate. Clin Obstet Gynecol. 1995;38(4):841–848.
   PubMed Web of Science ®Google Scholar
• Phillips A. The selectivity of a new progestin. Acta Obstet Gynecol Scand Suppl. 1990;152(s152):21–24.
   PubMedGoogle Scholar
• Phillips A, Hahn DW, Klimek S, et al. A comparison of the potencies and activities of progestogens used in contraceptives. Contraception. 1987;36(2):181–192.
   PubMed Web of Science ®Google Scholar
• Paris F, Balaguer P, Rimbault F, et al., Molecular action of norgestimate: new developments. Gynecol Endocrinol. 2015;31(6): 487–490.
   PubMed Web of Science ®Google Scholar
• Phillips A, Hahn DW, McGuire JL. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity. Am J Obstet Gynecol. 1992;167(4):1191–1196.
   PubMed Web of Science ®Google Scholar
• Phillips A, Demarest K, Hahn DW, et al. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception. 1990;41(4):399–410.
   PubMed Web of Science ®Google Scholar
• Anderson FD. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives. Acta Obstet Gynecol Scand. 1992;71(156):15–21.
   Google Scholar
• Paris F, Rabeolina F, Bacquet A, et al., Antiandrogenic activity of norgestimate in a human androgen-dependent stable-trasfected cell line. Gynecological Endocrinol. 2007;23(4): 193–197.
   PubMed Web of Science ®Google Scholar
• Gobinet J, Paujol N, Sultan C. Molecular action of androgens. Mol Cell Endocrinol. 2002;198(1–2):15–24.
   PubMed Web of Science ®Google Scholar
• Rittmaster RS. Clinical relevance of testosterone and dihydrotestosterone metabolism in women. Am J Med. 1995;98(1):17–21.
   Google Scholar
• Vermorken AJ, Goos JM, Roelofs HM. A method for the evaluation of the local antiandrogenic action of 5 alpha-reductase inhibitors on human skin. Br J Dermatol. 1980;102(6):695–701.
   PubMed Web of Science ®Google Scholar
• Anclersson S, Russell DW. Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. Proc Nut1 Acad Sci USA. 1990;87(10):3640–3644.
   PubMed Web of Science ®Google Scholar
• Aumuller G, Eicheler W, Renneberg H, et al. Immunocytochemical evidence for differential subcellular localization of 5α-reductase isoenzymes in human tissues. Acta Anat. 1996;156(4):241–252.
   PubMedGoogle Scholar
• Rabe T, Kowald A, Ortmann J, et al. Inhibition of skin 5α-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol. 2000;14(4):223–230.
   PubMed Web of Science ®Google Scholar
• Lete I, Chabbert-Buffet N, Jamin C, et al. Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: a literature review. Eur J Contracept Reprod HealthCare. 2015;20(5):329–343.
   PubMed Web of Science ®Google Scholar
• Odlind V, Milsom I, Persson I, et al. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand. 2002;81(6):482–490.
   PubMed Web of Science ®Google Scholar
• Phillips A, Hahn DW, McGuire JL. Relative binding affinity of norgestimate and other progestins for human sex hormone-binding globulin. Steroid. 1990;55(8):373–375.
   PubMed Web of Science ®Google Scholar
• Rott H. Contraception, venous thrombosis and biological plausibility. Minerva Med. 2013;104(2):161–167.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware RL, Menard J, Rad M, et al. Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. J Clin Endocrinol Metab. 2007;92(6):2074–2079.
   PubMed Web of Science ®Google Scholar
• Wiegratz I, Lee JH, Kutschera E, et al. Effect of four oral contraceptives on hemostatic parameters. Contraception. 2004;70(2):97–106.
   PubMed Web of Science ®Google Scholar
• Kluft C, Endrikat J, Mulder SM, et al. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. Contraception. 2006;73(4):336–343.
   PubMed Web of Science ®Google Scholar
• Grandi G, Facchinetti F, Bitzer J. Estradiol in hormonal contraception: real evolution or just same old wine in a new bottle? Eur J Contracept Reprod Health Care. 2017;22(4):245–246.
   PubMed Web of Science ®Google Scholar
• Grandi G, Barra F, Ferrero S, et al., Estradiol in non-oral hormonal contraception: a “long and winding road”. Expert Rev Endocrinol Metab. 2019;14(3): 153–155.
   PubMed Web of Science ®Google Scholar
• Isidori AM, Minnetti M, Sbardella E, et al. Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect. Eur J Endocrinol. 2015;173(3):R101–3.ù.
   PubMed Web of Science ®Google Scholar
• Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids. 2011;76:636–682.
   PubMed Web of Science ®Google Scholar
• Herkert O, Kuhl H, Sandow J, et al. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation. 2001;104(23):2826–2831.
   PubMed Web of Science ®Google Scholar
• Gromotowicz-Poplawska A, Stankiewicz A, Kramkowski K, et al. The acute prothrombotic effect of aldosterone in rats is partially mediated via angiotensin II receptor type 1. Thromb Res. 2016;138:114–120.
   PubMed Web of Science ®Google Scholar
• Sawathiparnich P, Kumar S, Vaughan DE, et al. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab. 2002;87(2):448–452.
   PubMed Web of Science ®Google Scholar
• Cagnacci A. Hormonal contraception: venous and arterial disease. Eur J Contracept Reprod Health Care. 2017;22(3):191–199.
   PubMed Web of Science ®Google Scholar
• Norris LA, Bonnar J. Haemostatic changes and the oral contraceptive pill. Baillieres Clin Obstet Gynaecol. 1997;11(3):545–563.
   PubMedGoogle Scholar
• Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicentre study. Contraception. 2003;67(3):173–185.
   PubMed Web of Science ®Google Scholar
• Darney PD. The androgenicity of progestins. Am J Med. 1995;98(1):104–110.
   PubMed Web of Science ®Google Scholar
• Deckers GH, Schoonen WG, Kloosterboer HJ. Influence of the substitution of 11-methylene, delta(15), and/or 18-methyl groups in norethisterone on receptor binding, transactivation assays and biological activities in animals. J Steroid Biochem Mol Biol. 2000;74(3):83–92.
   PubMed Web of Science ®Google Scholar
• Hugon-Rodin J, Gompel A, Plu-Bureau G. Epidemiology of hormonal contraceptives-related venous thromboembolism. Eur J Endocrinol. 2014;171(6):R221–30.
   PubMed Web of Science ®Google Scholar
• de Bastos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014;3:CD010813.
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø, Nielsen LH, Wessel Skovlund C, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: danish cohort study, 2001–9. BMJ. 2011;343:d6423.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency, Benefits of combined hormonal contraceptives (CHCs) continue to outweigh risks, 16 January 2014, available at https://www.ema.europa.eu/en/documents/referral/benefits-combined-hormonal-contraceptives-chcs-continue-outweigh-risks_en.pdf. last accessed 2020 Aug 5th
   Google Scholar
• van den Heuvel MW, van Bragt AJ, Alnabawy AK, et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72(3):168–174.
   PubMed Web of Science ®Google Scholar
• Runnebaum B, Grunwald K, Rabe T. The efficacy and tolerability of norgestimate/ethinyl estradiol (250 μg of norgestimate/35 μg of ethinyl estradiol): results of an open, multicenter study of 59,701 women. Am J Obstet Gynecol. 1992;166(6):1693–1698.
   Web of Science ®Google Scholar
• Huber J. Clinical experience with a new norgestimate-containing oral contraceptive. Int J Fertil. 1992;37 Suppl 1(suppl):47–53.
   PubMedGoogle Scholar
• Becker H. Supportive European data on a new oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand. 1990;152(s152):33–39.
   Google Scholar
• Gauthier A, Upmalis D, Dain M-P. Clinical evaluation of a new triphasic oral contraceptive: norgestimate and ethinyl estradiol. Acta Obstet Gynecol Scand. 1992;156(s156):27–32.
   Google Scholar
• Corson SL. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. U S Clinial Trials Acta Obstet Gynecol Scand. 1990;152(s152):25–31.
   PubMedGoogle Scholar
• London RS, Chapdelaine A, Upmalis D, et al. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. Acta Obstet Gynecol Scand. 1992;156(s156):9–14.
   Google Scholar
• Fotherby K. Oral contraceptives and lipids. BMJ. 1989;298(6680):1049–1050.
   PubMedGoogle Scholar
• Grandi G, Piacenti I, Volpe A, et al. Modification of body composition and metabolism during oral contraceptives containing non-androgenic progestins in association with estradiol or ethinyl estradiol. Gynecol Endocrinol. 2014;30(9):676–680.
   PubMed Web of Science ®Google Scholar
• Chapdelaine A, Desmarais J-L, Derman RJ. Clinical evidence of minimal androgenic activity of norgestimate. Int J Fertil. 1989;34(5):347–352.
   PubMedGoogle Scholar
• Wiegratz I, Jung-Hoffmann C, Gross W, et al. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters. Contraception. 1998;58(2):83–91. Aug.
   PubMed Web of Science ®Google Scholar
• Crook D, Godsland I. Safety evaluation of modern oral contraceptives. Effects on Lipoprotein and Carbohydrate Metabolism Contraception. 1998;57:189–201.
   PubMed Web of Science ®Google Scholar
• Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 1995;80(6):1816–1821.
   PubMed Web of Science ®Google Scholar
• Andolsek KM. Cycle control with triphasic norgestimate and ethinyl estradiol, new oral contraceptive agent. Acta Obstet Gynecol Scnd. 1992;156(s156):22–26.
   Google Scholar
• Tantbirojn P, Taneepanichskul S. Clinical comparative study of oral contraceptives containing 30 μg ethinylestradiol/150 μg levonorgestrel, and 35 μg ethinylestradiol/250 μg norgestimate in Thai women. Contraception. 2002;66(6):401–405.
   PubMed Web of Science ®Google Scholar
• Affinito P, Monterubbianesi M, Primizia M, et al. Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: gestodene/ethinyl estradiol and norgestimate/ethynilestradiol. Gynecol Endocrinol. 1993;7(4):259–266.
   PubMed Web of Science ®Google Scholar
• Janaud A, Rouffy J, Upmalis D, et al. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel. Acta Obstet Gynecol Scand. 1992;156(s156):33–38.
   Google Scholar
• Grandi G, Napolitano A, Cagnacci A. Metabolic impact of combined hormonal contraceptives containing estradiol. Expert Opin Drug Metab Toxicol. 2016;12(7):779–787.
   PubMed Web of Science ®Google Scholar
• Grandi G, Xholli A, Napolitano A, et al. Prospective measurement of blood pressure and heart rate over 24 h in women using combined oral contraceptives with estradiol. Contraception. 2014;90(5):529–534.
   PubMed Web of Science ®Google Scholar
• Corson SL. Efficay and safety of a monophasic and triphasic oral contraceptive containing norgestimate. Am J Obstet Gynecol. 1994;170(5):1556–1561.
   PubMed Web of Science ®Google Scholar
• Jaisamrarn U, Chaovisitraree S, Angsuwathana A, et al. A comparison of multiphasic oral contraceptives containing norgestimate or desogestrel in acne treatment: a randomized trial. Contraception. 2014;90(5):535–541.
   PubMed Web of Science ®Google Scholar
• Paterni I, Granchi C, Katzenellenbogen JA, et al. Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential. Steroids. 2014;90:13–29.
   PubMed Web of Science ®Google Scholar
• Nyberg S. Mood and physical symptoms improve in women with severe cyclical changes by taking an oral contraceptive containing 250-mcg norgestimate and 35-mcg ethinyl estradiol. Contraception. 2013;87(6):773–781.
   PubMed Web of Science ®Google Scholar
• Cibula D, Sindelka G, Hill M, et al., Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin. Hum Reprod. 2002;17(1): 76–82.
   PubMed Web of Science ®Google Scholar
• Aikins Murphy P, Brixner D. Hormonal contraceptive discontinuation patterns according to formulation: investigation of associations in an administrative claims database. Contraception. 2008;77(4):257–263.
   PubMed Web of Science ®Google Scholar
• Grandi G, Del Savio MC. Lopes da Silva-Filho A, et al. Estetrol (E4): the new estrogenic component of combined oral contraceptives. Expert Rev Clin Pharmacol. 2020;13(4):327–330.
   PubMed Web of Science ®Google Scholar
• Wenzl R, Bennink HC, van Beek A, et al. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 beta-estradiol. Fertil Steril. 1993;60(4):616–619.
   PubMed Web of Science ®Google Scholar
• Astedt B, Jeppsson S, Liedholm P, et al. Clinical trial of a new oral contraceptive pill containing the natural oestrogen 17 beta-oestradiol. Br J Obstet Gynaecol. 1979;86(9):732–736.
   PubMedGoogle Scholar
• Jackson E. Controversies in postpartum contraception: when is it safe to start oral contraceptives after childbirth? Thromb Res. 2011;12(Suppl 3):S35–9.
   Google Scholar
• Lindh I, Skjeldestad FE, Gemzell-Danielsson K, et al. Contraceptive use in the Nordic countries. Acta Obstet Gynecol Scand. 2017;96(1):19–28.
   PubMed Web of Science ®Google Scholar